Skip to main content
Caplight Logo









Elisigen

Elisigen

Private
SeoulEnterprise Softwarehttps://elisigen.com/

Last Round

Series C

Jan 19, 2026

Est. Valuation

$179M

Total Funding Raised

$78.45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Elisigen is a biotechnology company that develops AAV-based gene therapies to treat retinal and neurological diseases.

Sector

Enterprise Software

Verticals

Workflow Automation, Project Management, Platform-as-a-Service

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapybiotechnologyAAV therapydrug discoveryclinical trialsbiopharmavector engineeringretinal diseaseneurological diseasebiotech startupclinical-stage biotechR&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elisigen Comparables

Compare Elisigen with similar companies based on industry and business-model similarity.

No public comparables are available for Elisigen. Request access to learn about comparables coverage.

Request access

Elisigen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 19, 2026
Series BJun 3, 2021
Series AApr 30, 2019
SeedOct 25, 2018

Elisigen Investors

Notable investors and investment history

Elisigen investors
InvestorRounds
SV InvestmentSeries B
KB InvestmentSeries C
Seven Tree Equity PartnersSeries B
Ulmus InvestmentSeries B
Premier PartnersSeries C
NICE F&ISeries C
QUAD Investment ManagementSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    $29M round with participation from NH Investment & Securities and Premier Partners.

  • May 21, 2024

    Grew 67% QoQ, from 6 to 10 employees.

Elisigen Filings

Explore SEC and related filing metadata, where available.

Elisigen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Elisigen's valuation, stock price, and market status.

Is Elisigen a public or private company?

Elisigen is a private company.

What is the current stock price of Elisigen?

Elisigen is a private company with no public stock price. Caplight tracks Elisigen's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Elisigen worth (valuation)?

Elisigen's valuation is estimated at $179.0M based on funding round data.

Can I buy Elisigen stock?

Elisigen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Elisigen's last funding round?

Elisigen's most recent funding round was Series C on June 3, 2021.

Who are the main investors in Elisigen?

Key investors in Elisigen include SV Investment, KB Investment, Seven Tree Equity Partners, Ulmus Investment, Premier Partners.

Will Elisigen IPO soon?

No public IPO plans have been announced for Elisigen.

How can I track Elisigen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elisigen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range11
Year Founded2018
Last FundingJan 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?